Alethia Biotherapeutics Inc. is focused on developing innovative therapies targeting cancer, particularly through the inhibition of epithelial-to-mesenchymal transition (EMT). Their lead product, AB-16B5, is a humanized IgG2 monoclonal antibody designed to inhibit an EMT-inducing form of secreted clusterin (sCLU). Preclinical studies have shown that AB-16B5 effectively blocks EMT, leading to enhanced responses to standard chemotherapy treatments and reduced tumor invasion in various carcinoma models. The mechanism of action involves the antibody's ability to prevent the morphological and behavioral changes in cancer cells that are characteristic of EMT, which is crucial for metastasis and chemotherapy resistance.

In addition to its therapeutic applications, Alethia employs a proprietary technology called Subtractive Transcription-based Amplification of mRNA (STAR) to discover and validate disease-related genes. This technology allows for the identification of differentially expressed mRNA sequences, including rare ones, by amplifying unique sequences present in specific cellular samples. STAR's innovative approach minimizes bias in amplification, providing a more accurate representation of gene expression changes associated with disease states. This capability not only aids in the discovery of potential therapeutic targets but also enhances the validation process for new treatments, positioning Alethia at the forefront of cancer research and development.

Canada

Privately-held Montreal-based biotechnology company
Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. Currently having one clinical-stage program with phase I data. Portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology. Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline. Established strategic partnerships to access mAb generation, humanization, antibody-drug conjugates, and CHO production technologies

Alethia Biotherapeutics Inc.

Company Details